Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 7/20 | 0.68 |
| ▸ | ANPEP | P15144 | 3/20 | 0.68 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | REN | P00797 | 5/20 | 0.56 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Iv SCHEMBL4322224 | 1.00 | LNPEP (0.68) | LNPEPANPEPAGTR1AGTR2SLC6A2 | |
| SCHEMBL9010597 | 0.96 | LNPEP (0.64) | LNPEPANPEPAGTR1AGTR2REN | |
| SCHEMBL9010601 | 0.96 | LNPEP (0.64) | LNPEPANPEPAGTR1AGTR2REN | |
| SCHEMBL29619755 | 0.95 | LNPEP (0.63) | LNPEPANPEPAGTR1AGTR2SLC6A2 | |
| SCHEMBL4757569 | 0.94 | LNPEP (0.63) | LNPEPANPEPAGTR1AGTR2SLC6A2 | |
| SCHEMBL11204440 | 0.94 | LNPEP (0.60) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| SCHEMBL11204436 | 0.94 | LNPEP (0.60) | LNPEPANPEPAGTR1AGTR2NTSR2 | |
| SCHEMBL4757544 | 0.93 | LNPEP (0.60) | LNPEPANPEPAGTR1AGTR2SLC6A2 | |
| SCHEMBL29701255 | 0.93 | SLC6A2 (0.63) | LNPEPANPEPAGTR1AGTR2SLC6A2 | |
| SCHEMBL4756875 | 0.93 | LNPEP (0.60) | LNPEPANPEPAGTR1AGTR2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | claimed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | claimed |
| WO-2026090438-A1 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | DIRECT BIOLOGICS, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4633658-A1 | METHODS OF TREATING CARDIAC INJURY | Proletariat Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4021571-B1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-10-08 | — | — | EP | disclosed |
| EP-3607962-B1 | ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION | THE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORPORATION (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250206779-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2025-06-26 | — | — | US | disclosed |
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-07-07 | — | — | US | disclosed |
| EP-4021571-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-07-06 | — | — | EP | disclosed |
| US-20220193183-A1 | COMPOSITIONS AND METHODS FOR TREATING RENAL FAILURE | LA JOLLA PHARMA, LLC | 2022-06-23 | — | — | US | disclosed |
| CN-114556100-A | Therapy guidance and/or therapy monitoring for treatment of shock | 4TEEN4制药有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11331368-B2 | Angiotensin receptor agonists and uses thereof | MONASH UNIVERSITY (AU) | 2022-05-17 | — | — | US | disclosed |
| US-11306066-B2 | 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors | MONASH UNIVERSITY (AU) | 2022-04-19 | — | — | US | disclosed |
| US-20220047669-A1 | ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSION | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION | 2022-02-17 | — | — | US | disclosed |
| US-7619217-B2 | High power laser induced acoustic desorption probe | PURDUE RESEARCH FOUNDATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070295902-A1 | High power laser induced acoustic desorption probe | PURDUE RESEARCH FOUNDATION (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | LNPEP 2701/4885ANPEP 2488/4885AGTR1 242/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | LNPEP 3002/4885ANPEP 4516/4885AGTR1 1006/4885 |
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | DPP3, ACE, FABP3 | LNPEP 743/4885ANPEP 54/4885AGTR1 5/4885 |
| US-11306066-B2 | 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors | IAPP, ENPEP, DNPEP | LNPEP 30/4885ANPEP 13/4885AGTR1 566/4885 |
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | LNPEP 5/4885ANPEP 4/4885AGTR1 171/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | LNPEP 5/4885ANPEP 4/4885AGTR1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.